When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 4, 2013, Pages 431-444

  Steensma, David P ^a   Gattermann, Norbert ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

chelation therapy; deferasirox; deferiprone; deferoxamine; haemosiderosis; iron; myelodysplastic syndromes; red blood cell transfusion complications

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; IRON; IRON CHELATING AGENT; LABILE PLASMA IRON; NON TRANSFERRIN BOUND IRON; UNCLASSIFIED DRUG;

CHELATION THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; ERYTHROCYTE TRANSFUSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOCHROMATOSIS; HEPATOSPLENOMEGALY; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; IRON ABSORPTION; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; LONG TERM EXPOSURE; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMALL INTESTINE ABSORPTION; SURVIVAL;

CHELATION THERAPY; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HAEMOSIDEROSIS; IRON; MYELODYSPLASTIC SYNDROMES; RED BLOOD CELL TRANSFUSION [COMPLICATIONS];

CLINICAL TRIALS AS TOPIC; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MYELODYSPLASTIC SYNDROMES;

EID: 84893794762     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.09.009     Document Type: Review

References (102)

1. S.S. Bottomley Secondary iron overload disorders Semin Hematol 35 1998 77 86
2. D.P. Steensma Iron as the new radon Leuk Res 33 2008 1158 1163
3. A. Tefferi, and R.M. Stone Iron chelation therapy in myelodysplastic syndrome - Cui bono? Leukemia 23 2009 1373
4. N. Gattermann, and E.A. Rachmilewitz Iron overload in MDS-pathophysiology, diagnosis, and complications Ann Hematol 90 2011 1 10
5. H.A. Leitch Controversies surrounding iron chelation therapy for MDS Blood Rev 25 2011 17 31
6. D.P. Steensma The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate Curr Hematol Malig Rep 6 2011 136 144
7. V. Santini, D. Girelli, and A. Sanna et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes PLoS ONE 6 2011 e23109
8. T. Ganz Hepcidin and its role in regulating systemic iron metabolism Hematology (Am Soc Hematol Educ Progr) 2006 29 35
9. T. Tanno, N.V. Bhanu, and P.A. Oneal et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin Nat Med 13 2007 1096 1101
10. T. Tanno, P. Porayette, and O. Sripichai et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells of the iron regulatory protein hepcidin Blood 114 2009 181 186
11. N. Gattermann Clinical consequences of iron overload in myelodysplastic syndromes and treatment with chelators Hematol Oncol Clin North Am 19 Suppl. 1 2005 13 17
12. N. Gattermann, C. Finelli, and M.D. Porta et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study Leuk Res 34 2010 1143 1150
13. Z.I. Cabantchik, W. Breuer, and G. Zanninelli et al. LPI-labile plasma iron in iron overload Best Pract Res Clin Haematol 18 2005 277 287
14. J.B. Porter, R. Rafique, and S. Srichairatanakool et al. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use Ann N Y Acad Sci 1054 2005 155 168
15. L. Malcovati, M.G. Della Porta, and M. Cazzola Predicting survival and leukemic evolution in patients with myelodysplastic syndrome Haematologica 91 2006 1588 1590
16. G. Sanz, B. Nomdedeu, and E. Such et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome Blood 112 2008 640 (ASH annual meeting Abstracts)
17. H.A. Leitch, C. Chan, and C.S. Leger et al. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis Leuk Res 36 2012 Nov 1380 1386
18. C.E. Chee, D.P. Steensma, and W. Wu et al. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts Am J Hematol 83 2008 611 613
19. A.I. Schafer, R.G. Cheron, and R. Dluhy et al. Clinical consequences of acquired transfusional iron overload in adults N Engl J Med 304 1981 319 324
20. J.C. Wood, M. Otto-Duessel, and M. Aguilar et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of cardiomyopathy Circulation 112 2005 535 543
21. J.P. Carpenter, T. He, and P. Kirk et al. On T2* magnetic resonance and cardiac iron Circulation 123 2011 1519 1528
22. E.P. Alessandrino, S. Amadori, and G. Barosi et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology Haematologia 87 2002 1286 1306
23. D. Bowen, D. Culligan, and S. Jowitt et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes Br J Haematol 120 2003 187 200
24. National-Comprehensive-Cancer-Network NCCN clinical practice guidelines in oncology v.1: myelodysplastic syndromes 2011 Available from: http://www.nccn.org/professionals/physician-gls/pdf/mds.pdf
25. N. Gattermann, J.B. Porter, and L.F. Lopes et al. Consensus statement on iron overload in myelodysplastic syndromes Hematol Oncol Clin North Am 19 Suppl. 1 2005 18 25
26. T. Suzuki, M. Tomonaga, and Y. Miyazaki et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes Int J Hematol 88 2008 30 35
27. R.A. Wells, B. Leber, and R. Buckstein et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline Leuk Res 32 2008 1338 1353
28. B. Arrizabalaga, C. del Canizo, and A.F. Remacha et al. Guía clínica de quelación del paciente con síndrome mielodisplásico [Clinical guide to chelation therapy for patients with myelodysplastic syndrome (Spanish guidelines)] Haematologica 93 Suppl. 1 2008 3 10
29. P. Valent, O. Krieger, and R. Stauder et al. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform Eur J Clin Invest 38 2008 143 149
30. M. Mittelman, G. Lugassy, and D. Merkel et al. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines Isr Med Assoc J 10 2008 374 376
31. J.M. Bennett MDS Foundation's Working Group on Transfusional Iron Overload Consensus statement on iron overload in myelodysplastic syndromes Am J Hematol 83 2008 858 861
32. V. Santini, P.E. Alessandrino, and E. Angelucci et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES; GITMO practice guidelines Leuk Res 34 2010 1576 1588
33. S.L. Goldberg, E. Chen, and M. Corral et al. Incidence and clinical complications of myelodysplastic syndromes among United States medicare beneficiaries J Clin Oncol 28 2010 2847 2852
34. L. Malcovati, M.G. Della Porta, and C. Pascutto et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 2005 7594 7603
35. M. Takatoku, T. Uchiyama, and S. Okamoto et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload in morbidity/mortality Eur J Haematol 78 2007 487 494
36. F. Dayyani, A.P. Conley, and S.S. Strom et al. Cause of death in patients with lower-risk myelodysplastic syndrome Cancer 116 2010 2174 2179
37. J.J. Bullen, H.J. Rogers, and P.B. Spalding et al. Natural resistance, iron and infection: a challenge for clinical medicine J Med Microbiol 55 2006 251 258
38. C. Peddie, C.R. Wolf, and L.I. McLellan et al. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration Br J Haematol 99 1997 625 631
39. D. Bowen, L. Wang, and M. Frew et al. Antioxidant enzyme expression in myelodysplastic and acute myeloid leukemia bone marrow: further evidence of a pathogenetic role for oxidative stres? Haematologica 88 2003 1070 1072
40. B. Novotna, Y. Bagryantseva, and M. Siskova et al. Oxidative damage in bone marrow cells of patients with low-risk myelodysplastic syndrome Leuk Res 33 2009 340 343
41. H. Ghoti, J. Amer, and A. Winder et al. Oxidative stress in red blood cells, platelets, and polymorphonuclear leukocytes from patients with myelodysplastic syndromes Eur J Haematol 79 2007 463 467
42. E. Messa, D. Cilloni, and F. Messa et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis Acta Haematol 120 2008 70 74
43. P. Capalbo, G. Spinosa, and M.G. Franzese et al. Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements Acta Haematol 121 2009 19 20
44. H. Okabe, T. Suzuki, and T. Omori et al. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome Rinsho Ketsueki 50 2009 1626 1629
45. M.A. Badawi, L. Vickars, and J.M. Chase Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome Adv Hematol 2010 2010 164045
46. E.N. Oliva, F. Ronco, and A. Marino et al. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients Transfusion 50 2010 1568 1570
47. A. Molteni, M. Riva, and V. Speziale et al. Iron-chelation therapy in MDS/IMF patients: does it really impact on transfusion requirements? Haematologica 95 Suppl. 2 2010 566 abs. 1410
48. T. Nishiuchi, Y. Okutani, and T. Fujita et al. Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome Int J Hematol 91 2010 333 335
49. M. Breccia, G. Loglisci, and A. Salaroli et al. Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response Acta Haematol 124 2010 46 48
50. R. Guariglia, M.C. Martorelli, and O. Villani et al. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review Leuk Res 35 2010 566 570
51. S. Improta, M.R. Villa, and A. Volpe et al. Iron overload in low-risk myelodysplastic syndromes (MDS): a multicentric study Leuk Res 35 Suppl. 1 2011 S141
52. M. Vascilica, A. Tatic, and A. Bardas Iron chelation therapy with deferasirox in transfusion dependent myelodysplastic syndrome patients Haematologica 96 s2 2011 525 (abstract 1289)
53. D. Cilloni, E. Messa, and L. Biale et al. High rate of erythroid response during iron chelation therapy in a cohort of 105 patients affected by hematologic malignancies with transfusional iron overload: an Italian multicenter retrospective study Blood 118 2011 ASH abstract 611
54. N. Gattermann, C. Finelli, and M. Della Porta et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes Haematologica 97 2012 1364 1371
55. A.F. List, M.R. Baer, and D.P. Steensma et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome J Clin Oncol 30 2012 2134 2139
56. P.D. Jensen, L. Heickendorff, and B. Pedersen et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload Br J Haematol 94 1996 288 299
57. S. Kikuchi, M. Kobune, and S. Iyama et al. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox Free Radic Biol Med 53 2012 643 648
58. L.S.A. Chan, L.C. Gu, and M.J. Rauh et al. Iron overload accelerates development of leukaemia: evidence from a mouse model Blood 116 2010 abstract 122
59. M. Durken, P. Nielsen, and S. Knobel et al. Nontransferrin-bound iron in serum of patients receiving bone marrow transplants Free Radic Biol Med 22 1997 1159 1163
60. L. Sahlstedt, F. Ebeling, and L. von Bonsdorff et al. Non-transferrin-bound iron during allogeneic stem cell transplantation Br J Haematol 113 2001 836 838
61. A.M. Evens, J. Mehta, and L.I. Gordon Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress Bone Marrow Transpl 34 2004 561 571
62. E.P. Alessandrino, M.G. Della Porta, and A. Bacigalupo et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study Haematologica 95 2010 476 484
63. P. Armand, H.T. Kim, and C. Cutler et al. Prognostic impact of elevated pre-transplant serum ferritin in patients undergoing myeloablative stem cell transplantation Blood 109 2007 4586 4588
64. H.A. Leitch, C.S. Leger, and T.A. Goodman et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy Clin Leuk 2 2008 205 211
65. C. Rose, S. Brechignac, and D. Vassilief et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDs patients? A multicenter study by the GFM Leuk Res 34 2010 864 870
66. J. Neukirchen, F. Fox, and A. Kundgen et al. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Dusseldorf MDS registry Leuk Res 36 2012 1067 1070
67. N.B. Roy, S. Myerson, and A.H. Schuh et al. Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes Br J Haematol 154 2011 521 524
68. F. Di Gregorio, M. Romeo, and G. Pizzarelli et al. An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients Br J Haematol 98 1997 601 602
69. C. Borgna-Pignatti, and A. Cohen Evaluation of a new method of administration of the iron chelating agent deferoxamine J Pediatr 130 1997 86 88
70. M. Franchini, G. Gandini, and M. de Gironcoli et al. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload Blood 95 2000 2776 2779
71. J.P. Kushner, J.B. Porter, and N.F. Olivieri Secondary iron overload Hematology (Am Soc Hematol Educ Progr) 2001 47 61
72. B.A. Davis, and J.B. Porter Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia Blood 95 2000 1229 1236
73. G.M. Brittenham, P.M. Griffith, and A.W. Nienhuis et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major N Engl J Med 331 1994 567 573
74. A.V. Hoffbrand, F. Al-Refaie, and B. Davis et al. Long-term deferiprone in 51 transfusion-dependent iron overloaded patients Blood 91 1998 295 300
75. N. Olivieri, G.M. Brittenham, and C.E. McLaren et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major N Engl J Med 339 1998 417 423
76. K.V. Kowdley, and M.M. Kaplan Iron-chelation therapy with oral deferiprone - toxicity or lack of efficacy? N Engl J Med 339 1998 468
77. A. Ceci, P. Baiardi, and M. Felisi et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients Br J Haematol 118 2002 330
78. L.J. Anderson, B. Wonke, and E. Prescott et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia Lancet 360 2002 516 520
79. D.J. Pennell Randomized controlled trial of deriprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis Blood 107 2006 3738 3744
80. A.R. Cohen, R. Galanello, and A. Piga et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone Blood 102 2003 1583 1587
81. I.R. Wanless, G. Sweeney, and A.P. Dhillon et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia Blood 100 2002 1566 1569
82. J. Cermak, A. Jonasova, and J. Vondrakova et al. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome Hemoglobin 35 2011 217 227
83. M.J. Kersten, R. Lange, and M.E. Smeets et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial Ann Hematol 73 1996 247 252
84. F.H. Mourad, A.V. Hoffbrand, and M. Sheikh-Taha et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients Br J Haematol 121 2003 187 189
85. E. D'Angelo, N. Mirra, and A. Rocca et al. Combined therapy with desferrioxamine and deferiprone: a new protocol for iron chelation in thalassemia J Pediatr Hematol Oncol 26 2004 451 453
86. K.H. Wu, J.S. Chang, and C.H. Tsai et al. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with b-thalassaemia major Ann Hematol 83 2004 471 473
87. V. Alymara, D. Bourantas, and A. Chaidos et al. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone Hematol J 5 2004 475 479
88. M.A. Tanner, R. Galanello, and C. Dessi et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance Circulation 115 2007 1876 1884
89. S. Gomber, R. Saxena, and N. Madan Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children Indian Pediatr 41 2004 21 27
90. M.E. Lai, R.W. Grady, and S. Vacquer et al. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone Blood Cells Mol Dis 45 2010 136 139
91. R. Galanello, A. Agus, and S. Campus et al. Combined iron chelation therapy Ann N Y Acad Sci 1202 2010 79 86
92. A. Piga, R. Galanello, and G.L. Forni et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload Haematologica 91 2006 873 880
93. M.D. Cappellini, A. Cohen, and A. Piga et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia Blood 107 2006 3455 3462
94. J. Porter, R. Galanello, and G. Saglio et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anemias to deferasirox (ICL670): a 1-yr prospective study Eur J Haematol 80 2008 168 176
95. F. Nolte, E. Angelucci, and P. Beris et al. Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox Leuk Res 35 2011 1131 1135
96. M.D. Cappellini, J. Porter, and A. El-Beshlawy et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias Haematologica 95 2010 557 566
97. N. Gattermann, A. Jarisch, and R. Schlag et al. Deferasirox treatment of iron-overloaded chelation-naive and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange Eur J Haematol 88 2012 260 268
98. M. Breccia, P. Finsinger, and G. Loglisci et al. Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population Ann Hematol 91 2012 1345 1349
99. F. Nolte, B. Hochsmann, and A. Giagounidis et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload Ann Hematol 92 2013 191 198
100. E.J. Neufeld, R. Galanello, and V. Viprakasit et al. A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload Blood 119 2012 3263 3268
101. S. Mukhopadhyay, J. Basak, and M. Kar et al. The role of iron chelation activity of wheat grass juice in patients with myelodysplastic syndrome J Clin Oncol 27 2009 15s suppl; abstr 7012
102. A.V. Hoffbrand, A. Taher, and M.D. Cappellini How I treat transfusional iron overload Blood 120 2012 3657 3669